{"id":548753,"date":"2025-11-04T15:53:13","date_gmt":"2025-11-04T15:53:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/548753\/"},"modified":"2025-11-04T15:53:13","modified_gmt":"2025-11-04T15:53:13","slug":"france-lauxera-targets-final-close-of-e500m-for-second-fund","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/548753\/","title":{"rendered":"France: Lauxera targets final close of \u20ac500m for second fund"},"content":{"rendered":"<p>Healthcare focused asset manager, Lauxera Capital Partners, has closed its Growth Fund II at \u20ac400m, and is eyeing a final close of \u20ac500m by the end of the year, according to a release on its website. The most recent close follows its <a href=\"https:\/\/www.investorsinhealthcare.com\/articles\/category\/news\/france-lauxera-announces-first-close-of-growth-ii-at-e300m\/\" target=\"_blank\" rel=\"noopener\">initial close in December 2024 at \u20ac300m<\/a>.<\/p>\n<p>In August of 2025, Tokyo-listed,\u00a0<a href=\"https:\/\/www.investorsinhealthcare.com\/articles\/category\/news\/uk-terumo-to-acquire-organox-for-us1-5bn\/\" target=\"_blank\" rel=\"noopener\">Terumo, is a global medical device company originating from Japan, \u00a0acquired\u00a0Lauxera portfolio company OrganOx<\/a>, a UK-based innovator in organ preservation devices, in a transaction valued at approximately US$1.5bn. It was one of the largest-ever deals in the UK medtech sector and one of the biggest spinouts from Oxford University.<\/p>\n<p>In February 2022, Lauxera closed Growth I at more than \u20ac260m with funds dedicated to financing innovative HealthTech companies.<\/p>\n","protected":false},"excerpt":{"rendered":"Healthcare focused asset manager, Lauxera Capital Partners, has closed its Growth Fund II at \u20ac400m, and is eyeing&hellip;\n","protected":false},"author":2,"featured_media":548754,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5309],"tags":[2000,299,36,130392],"class_list":{"0":"post-548753","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-france","8":"tag-eu","9":"tag-europe","10":"tag-france","11":"tag-lauxera-capital-partners"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/548753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=548753"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/548753\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/548754"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=548753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=548753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=548753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}